{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:05:53Z","timestamp":1794035153714,"version":"4.8.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lewy body (LB) diseases, characterized by the aggregation of misfolded \u03b1-synuclein proteins, exhibit notable clinical heterogeneity. This may be due to variations in accumulation patterns of LB neuropathology. Here we apply a data-driven disease progression model to regional neuropathological LB density scores from 814 brain donors with Lewy pathology. We describe three inferred trajectories of LB pathology that are characterized by differing clinicopathological presentation and longitudinal antemortem clinical progression. Most donors (81.9%) show earliest pathology in the olfactory bulb, followed by accumulation in either limbic (60.8%) or brainstem (21.1%) regions. The remaining donors (18.1%) initially exhibit abnormalities in brainstem regions. Early limbic pathology is associated with Alzheimer\u2019s disease-associated characteristics while early brainstem pathology is associated with progressive motor impairment and substantial LB pathology outside of the brain. Our data provides evidence for heterogeneity in the temporal spread of LB pathology, possibly explaining some of the clinical disparities observed in Lewy body disease.<\/jats:p>","DOI":"10.1038\/s41467-024-49402-x","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T11:02:03Z","timestamp":1718449323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Disease progression modelling reveals heterogeneity in trajectories of Lewy-type \u03b1-synuclein pathology"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2759-9588","authenticated-orcid":false,"given":"Sophie E.","family":"Mastenbroek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-9940","authenticated-orcid":false,"given":"Jacob W.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-1762","authenticated-orcid":false,"given":"Lyduine E.","family":"Collij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geidy E.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cilia","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7772-781X","authenticated-orcid":false,"given":"Alexandra L.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly A.","family":"Shill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika D.","family":"Driver-Dunckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamal H.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Belden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parichita","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-3706","authenticated-orcid":false,"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-7477","authenticated-orcid":false,"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"49402_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"49402_CR2","unstructured":"Galaz, Z. et al. in Intertwining Graphonomics with Human Movements (eds Cristina Carmona-Duarte, Moises Diaz, Miguel A. Ferrer, & Aythami Morales) 255\u2013268 (Springer International Publishing, 2022)."},{"key":"49402_CR3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"49402_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"49402_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.parkreldis.2022.07.014","volume":"102","author":"F Albrecht","year":"2022","unstructured":"Albrecht, F. et al. Unraveling Parkinson\u2019s disease heterogeneity using subtypes based on multimodal data. Parkinsonism Relat. Disord. 102, 19\u201329 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49402_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","volume":"28","author":"GT Stebbins","year":"2013","unstructured":"Stebbins, G. T. et al. How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson\u2019s disease rating scale: comparison with the unified Parkinson\u2019s disease rating scale. Mov. Disord. 28, 668\u2013670 (2013).","journal-title":"Mov. Disord."},{"key":"49402_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-021-00946-w","volume":"14","author":"C Abdelnour","year":"2022","unstructured":"Abdelnour, C. et al. Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimer\u2019s Res. Ther. 14, 14 (2022).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"49402_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3233\/JAD-180167","volume":"64","author":"E Morenas-Rodr\u00edguez","year":"2018","unstructured":"Morenas-Rodr\u00edguez, E. et al. Clinical subtypes of dementia with lewy bodies based on the initial clinical presentation. J. Alzheimer\u2019s Dis. 64, 505\u2013513 (2018).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"49402_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41531-023-00556-3","volume":"9","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Two distinct trajectories of clinical and neurodegeneration events in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 111 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"49402_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jnen\/nlz080","volume":"78","author":"CH Adler","year":"2019","unstructured":"Adler, C. H. et al. Unified staging system for Lewy body disorders: clinicopathologic correlations and comparison to Braak staging. J. Neuropathol. Exp. Neurol. 78, 891\u2013899 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"49402_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.14698","volume":"150","author":"L Walker","year":"2019","unstructured":"Walker, L., Stefanis, L. & Attems, J. Clinical and neuropathological differences between Parkinson\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies\u2014current issues and future directions. J. Neurochem. 150, 467\u2013474 (2019).","journal-title":"J. Neurochem."},{"key":"49402_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.brainresbull.2009.06.018","volume":"80","author":"E K\u00f6vari","year":"2009","unstructured":"K\u00f6vari, E., Horvath, J. & Bouras, C. Neuropathology of Lewy body disorders. Brain Res. Bull. 80, 203\u2013210 (2009).","journal-title":"Brain Res. Bull."},{"key":"49402_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00401-015-1526-9","volume":"131","author":"JB Toledo","year":"2016","unstructured":"Toledo, J. B. et al. Pathological \u03b1-synuclein distribution in subjects with coincident Alzheimer\u2019s and Lewy body pathology. Acta Neuropathol. 131, 393\u2013409 (2016).","journal-title":"Acta Neuropathol."},{"key":"49402_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"49402_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak, H., R\u00fcb, U., Gai, W. P. & Del Tredici, K. Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110, 517\u2013536 (2003).","journal-title":"J. Neural Transm."},{"key":"49402_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ana.21541","volume":"64","author":"RE Burke","year":"2008","unstructured":"Burke, R. E., Dauer, W. T. & Vonsattel, J. P. A critical evaluation of the Braak staging scheme for Parkinson\u2019s disease. Ann. Neurol. 64, 485\u2013491 (2008).","journal-title":"Ann. Neurol."},{"key":"49402_CR17","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3233\/JPD-212733","volume":"11","author":"TG Beach","year":"2021","unstructured":"Beach, T. G. et al. Vagus nerve and stomach synucleinopathy in parkinson\u2019s disease, incidental lewy body disease, and normal elderly subjects: evidence against the \u201cbody-first\u201d hypothesis. J. Parkinsons Dis. 11, 1833\u20131843 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"49402_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach, T. G. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613\u2013634 (2009).","journal-title":"Acta Neuropathol."},{"key":"49402_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3233\/JPD-202481","volume":"11","author":"P Borghammer","year":"2021","unstructured":"Borghammer, P. The \u03b1-synuclein origin and connectome model (SOC Model) of Parkinson\u2019s disease: explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J. Parkinson\u2019s Dis. 11, 455\u2013474 (2021).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"49402_CR20","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer, P. & Van Den Berge, N. Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis. J. Parkinson\u2019s Dis. 9, S281\u2013S295 (2019).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"49402_CR21","doi-asserted-by":"publisher","unstructured":"Aksman, L. M. et al. pySuStaIn: a Python implementation of the Subtype and Stage Inference algorithm. SoftwareX 16. https:\/\/doi.org\/10.1016\/j.softx.2021.100811 (2021).","DOI":"10.1016\/j.softx.2021.100811"},{"key":"49402_CR22","doi-asserted-by":"publisher","unstructured":"Young, A. L. et al. Ordinal SuStaIn: Subtype and Stage Inference for Clinical Scores, Visual Ratings, and Other Ordinal Data. Frontiers in Artificial Intelligence 4. https:\/\/doi.org\/10.3389\/frai.2021.613261 (2021).","DOI":"10.3389\/frai.2021.613261"},{"key":"49402_CR23","doi-asserted-by":"publisher","unstructured":"Young, A. L. et al. Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies. Brain. https:\/\/doi.org\/10.1093\/brain\/awad145 (2023).","DOI":"10.1093\/brain\/awad145"},{"key":"49402_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/neup.12189","volume":"35","author":"TG Beach","year":"2015","unstructured":"Beach, T. G. et al. Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology 35, 354\u2013389 (2015).","journal-title":"Neuropathology"},{"key":"49402_CR25","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863\u20131872 (2005).","journal-title":"Neurology"},{"key":"49402_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","volume":"119","author":"TG Beach","year":"2010","unstructured":"Beach, T. G. et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119, 689\u2013702 (2010).","journal-title":"Acta Neuropathol."},{"key":"49402_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/ane.13028","volume":"139","author":"R Savica","year":"2019","unstructured":"Savica, R. et al. Lewy body pathology in Alzheimer\u2019s disease: a clinicopathological prospective study. Acta Neurol. Scand. 139, 76\u201381 (2019).","journal-title":"Acta Neurol. Scand."},{"key":"49402_CR28","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"49402_CR29","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti, C. et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat. Med. 29, 1964\u20131970 (2023).","journal-title":"Nat. Med."},{"key":"49402_CR30","doi-asserted-by":"publisher","first-page":"e0217566","DOI":"10.1371\/journal.pone.0217566","volume":"14","author":"M Malek-Ahmadi","year":"2019","unstructured":"Malek-Ahmadi, M. et al. Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS One 14, e0217566 (2019).","journal-title":"PLoS One"},{"key":"49402_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/01.jnen.0000205145.54457.ea","volume":"65","author":"V Deramecourt","year":"2006","unstructured":"Deramecourt, V. et al. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 65, 278\u2013288 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"49402_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaneurol.2016.4926","volume":"74","author":"J Graff-Radford","year":"2017","unstructured":"Graff-Radford, J. et al. Duration and pathologic correlates of Lewy body disease. JAMA Neurol. 74, 310\u2013315 (2017).","journal-title":"JAMA Neurol."},{"key":"49402_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","volume":"16","author":"WW Barker","year":"2002","unstructured":"Barker, W. W. et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis. Assoc. Disord. 16, 203\u2013212 (2002).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"49402_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1212\/WNL.0b013e3181c7da8e","volume":"74","author":"MA Burack","year":"2010","unstructured":"Burack, M. A. et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74, 77\u201384 (2010).","journal-title":"Neurology"},{"key":"49402_CR35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","volume":"72","author":"DJ Irwin","year":"2012","unstructured":"Irwin, D. J. et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587\u2013598 (2012).","journal-title":"Ann. Neurol."},{"key":"49402_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","volume":"23","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh, M. N. et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis. Assoc. Disord. 23, 295\u2013297 (2009).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"49402_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1385\/JMN:17:2:225","volume":"17","author":"PT Kotzbauer","year":"2001","unstructured":"Kotzbauer, P. T., Trojanowski, J. Q. & Lee, V. M. Y. Lewy body pathology in Alzheimer\u2019s disease. J. Mol. Neurosci. 17, 225\u2013232 (2001).","journal-title":"J. Mol. Neurosci."},{"key":"49402_CR38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton, R. L. Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10, 378\u2013384 (2000).","journal-title":"Brain Pathol."},{"key":"49402_CR39","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1001\/archneur.61.12.1915","volume":"61","author":"A Popescu","year":"2004","unstructured":"Popescu, A., Lippa, C. F., Lee, V. M.-Y. & Trojanowski, J. Q. Lewy bodies in the amygdala: increase of \u03b1-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch. Neurol. 61, 1915\u20131919 (2004).","journal-title":"Arch. Neurol."},{"key":"49402_CR40","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0002-9440(10)65722-7","volume":"153","author":"CF Lippa","year":"1998","unstructured":"Lippa, C. F. et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer\u2019s disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365\u20131370 (1998).","journal-title":"Am. J. Pathol."},{"key":"49402_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2019.10.010","volume":"105","author":"F Bassil","year":"2020","unstructured":"Bassil, F. et al. Amyloid-beta (A\u03b2) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of Lewy body disorders with A\u03b2 pathology. Neuron 105, 260\u2013275.e266 (2020).","journal-title":"Neuron"},{"key":"49402_CR42","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","volume":"67","author":"C Ballard","year":"2006","unstructured":"Ballard, C. et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67, 1931\u20131934 (2006).","journal-title":"Neurology"},{"key":"49402_CR43","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","volume":"79","author":"P Edison","year":"2008","unstructured":"Edison, P. et al. Amyloid load in Parkinson\u2019s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 79, 1331 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"49402_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neulet.2010.09.036","volume":"486","author":"H Fujishiro","year":"2010","unstructured":"Fujishiro, H. et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci. Lett. 486, 19\u201323 (2010).","journal-title":"Neurosci. Lett."},{"key":"49402_CR45","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jnen\/nlw070","volume":"75","author":"DH Hepp","year":"2016","unstructured":"Hepp, D. H. et al. Distribution and load of amyloid-\u03b2 pathology in Parkinson disease and dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 75, 936\u2013945 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"49402_CR46","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","volume":"73","author":"SN Gomperts","year":"2016","unstructured":"Gomperts, S. N. et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol. 73, 1334\u20131341 (2016).","journal-title":"JAMA Neurol."},{"key":"49402_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1016-8","volume":"16","author":"KA Jellinger","year":"2018","unstructured":"Jellinger, K. A. & Korczyn, A. D. Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease? BMC Med. 16, 34 (2018).","journal-title":"BMC Med."},{"key":"49402_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1469-7580.2007.00748.x","volume":"211","author":"PS Hubbard","year":"2007","unstructured":"Hubbard, P. S., Esiri, M. M., Reading, M., McShane, R. & Nagy, Z. Alpha-synuclein pathology in the olfactory pathways of dementia patients. J. Anat. 211, 117\u2013124 (2007).","journal-title":"J. Anat."},{"key":"49402_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak, H., Ghebremedhin, E., R\u00fcb, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 318, 121\u2013134 (2004).","journal-title":"Cell Tissue Res."},{"key":"49402_CR50","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson, E. et al. Vagotomy and subsequent risk of Parkinson\u2019s disease. Ann. Neurol. 78, 522\u2013529 (2015).","journal-title":"Ann. Neurol."},{"key":"49402_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105626","volume":"164","author":"J Horsager","year":"2022","unstructured":"Horsager, J., Knudsen, K. & Sommerauer, M. Clinical and imaging evidence of brain-first and body-first Parkinson\u2019s disease. Neurobiol. Dis. 164, 105626 (2022).","journal-title":"Neurobiol. Dis."},{"key":"49402_CR52","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"49402_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00702-023-02633-6","volume":"130","author":"P Borghammer","year":"2023","unstructured":"Borghammer, P. The brain-first vs. body-first model of Parkinson\u2019s disease with comparison to alternative models. J. Neural Transm. 130, 737\u2013753 (2023).","journal-title":"J. Neural Transm."},{"key":"49402_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13075","volume":"32","author":"C Tremblay","year":"2022","unstructured":"Tremblay, C. et al. Effect of olfactory bulb pathology on olfactory function in normal aging. Brain Pathol. 32, e13075 (2022).","journal-title":"Brain Pathol."},{"key":"49402_CR55","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1007\/s00415-019-09540-5","volume":"266","author":"S Nag","year":"2019","unstructured":"Nag, S. et al. Neocortical Lewy bodies are associated with impaired odor identification in community-dwelling elders without clinical PD. J. Neurol. 266, 3108\u20133118 (2019).","journal-title":"J. Neurol."},{"key":"49402_CR56","doi-asserted-by":"publisher","unstructured":"Zucco, G. M., Rovatti, F. & Stevenson, R. J. Olfactory asymmetric dysfunction in early Parkinson patients affected by unilateral disorder. Front. Psychol. 6. https:\/\/doi.org\/10.3389\/fpsyg.2015.01020 (2015).","DOI":"10.3389\/fpsyg.2015.01020"},{"key":"49402_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2018.06.022","volume":"56","author":"YS Oh","year":"2018","unstructured":"Oh, Y. S., Kim, J. S., Hwang, E. J. & Lyoo, C. H. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson\u2019s disease. Parkinsonism Relat. Disord. 56, 47\u201351 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49402_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-020-00205-z","volume":"56","author":"KH Rashed","year":"2020","unstructured":"Rashed, K. H. et al. Patterns of olfactory dysfunctions in patients with Parkinson disease. Egypt. J. Neurol. Psychiatry Neurosurg. 56, 73 (2020).","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"49402_CR59","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1093\/brain\/awaa327","volume":"143","author":"R Smith","year":"2020","unstructured":"Smith, R. et al. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain 143, 3805\u20133815 (2020).","journal-title":"Brain"},{"key":"49402_CR60","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1097\/00001756-200210070-00028","volume":"13","author":"GJ Ho","year":"2002","unstructured":"Ho, G. J. et al. Age at onset is associated with disease severity in Lewy body variant and Alzheimer\u2019s disease. Neuroreport 13, 1825\u20131828 (2002).","journal-title":"Neuroreport"},{"key":"49402_CR61","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016).","journal-title":"Brain"},{"key":"49402_CR62","first-page":"748","volume":"140","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748\u2013763 (2017).","journal-title":"Brain"},{"key":"49402_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0891988706297086","volume":"20","author":"GA Marshall","year":"2007","unstructured":"Marshall, G. A., Fairbanks, L. A., Tekin, S., Vinters, H. V. & Cummings, J. L. Early-onset Alzheimer\u2019s disease is associated with greater pathologic burden. J. Geriatr. Psychiatry Neurol. 20, 29\u201333 (2007).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"49402_CR64","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1212\/WNL.38.1.48","volume":"38","author":"LA Hansen","year":"1988","unstructured":"Hansen, L. A., DeTeresa, R., Davies, P. & Terry, R. D. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer\u2019s disease. Neurology 38, 48\u201348 (1988).","journal-title":"Neurology"},{"key":"49402_CR65","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3233\/JAD-170129","volume":"60","author":"I Koychev","year":"2017","unstructured":"Koychev, I. et al. PET tau and amyloid-\u03b2 burden in mild Alzheimer\u2019s Disease: divergent relationship with age, cognition, and cerebrospinal fluid biomarkers. J. Alzheimers Dis. 60, 283\u2013293 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"49402_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32592-7","volume":"13","author":"L Frontzkowski","year":"2022","unstructured":"Frontzkowski, L. et al. Earlier Alzheimer\u2019s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading. Nat. Commun. 13, 4899 (2022).","journal-title":"Nat. Commun."},{"key":"49402_CR67","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain 141, 1517\u20131528 (2018).","journal-title":"Brain"},{"key":"49402_CR68","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1093\/brain\/awad100","volume":"146","author":"DI Bocancea","year":"2023","unstructured":"Bocancea, D. I. et al. Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis. Brain 146, 3719\u20133734 (2023).","journal-title":"Brain"},{"key":"49402_CR69","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnen\/nlw026","volume":"75","author":"A Serrano-Pozo","year":"2016","unstructured":"Serrano-Pozo, A. et al. Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum. J. Neuropathol. Exp. Neurol. 75, 516\u2013526 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"49402_CR70","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.parkreldis.2019.03.023","volume":"64","author":"DG Coughlin","year":"2019","unstructured":"Coughlin, D. G. et al. Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but \u2018failure to fit\u2019 is highly dependent on staging system applied. Parkinsonism Relat. Disord. 64, 124\u2013131 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49402_CR71","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","volume":"141","author":"J Attems","year":"2021","unstructured":"Attems, J. et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 141, 159\u2013172 (2021).","journal-title":"Acta Neuropathol."},{"key":"49402_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 (2023).","journal-title":"Nat. Commun."},{"key":"49402_CR73","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara, H. et al. \u03b1-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160\u2013164 (2002).","journal-title":"Nat. Cell Biol."},{"key":"49402_CR74","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.expneurol.2012.11.020","volume":"240","author":"DG Walker","year":"2013","unstructured":"Walker, D. G. et al. Changes in properties of serine 129 phosphorylated \u03b1-synuclein with progression of Lewy-type histopathology in human brains. Exp. Neurol. 240, 190\u2013204 (2013).","journal-title":"Exp. Neurol."},{"key":"49402_CR75","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra, S. S. et al. The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology 41, 479\u2013486 (1991).","journal-title":"Neurology"},{"key":"49402_CR76","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/atm.2016.10.67","volume":"4","author":"Z Zhang","year":"2016","unstructured":"Zhang, Z. Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann. Transl. Med. 4, 30 (2016).","journal-title":"Ann. Transl. Med."},{"key":"49402_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00401-004-0950-z","volume":"109","author":"DW Dickson","year":"2005","unstructured":"Dickson, D. W. Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol. 109, 14\u201324 (2005).","journal-title":"Acta Neuropathol."},{"key":"49402_CR78","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson, D. W. et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150\u20131157 (2009).","journal-title":"Lancet Neurol."},{"key":"49402_CR79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb, D. J., Oliver, E. & Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33\u201339 (1999).","journal-title":"Arch. Neurol."},{"key":"49402_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimers Dement."},{"key":"49402_CR81","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","volume":"122","author":"IR Mackenzie","year":"2011","unstructured":"Mackenzie, I. R. et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111\u2013113 (2011).","journal-title":"Acta Neuropathol."},{"key":"49402_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 123, 1\u201311 (2012).","journal-title":"Acta Neuropathol."},{"key":"49402_CR83","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Rom\u00e1n","year":"1993","unstructured":"Rom\u00e1n, G. C. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250\u2013260 (1993).","journal-title":"Neurology"},{"key":"49402_CR84","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic, J. et al. Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40, 1529\u20131534 (1990).","journal-title":"Neurology"},{"key":"49402_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05892-0","volume":"9","author":"AL Young","year":"2018","unstructured":"Young, A. L. et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat. Commun. 9, 4273 (2018).","journal-title":"Nat. Commun."},{"key":"49402_CR86","unstructured":"RStudio, T. RStudio: integrated development for R. RStudio, Inc., Boston, MA URL: https:\/\/www.rstudio.com42, 84 (2015)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49402-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T12:02:40Z","timestamp":1718452960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49402-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["49402"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-49402-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.12.05.569878","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.E.C. has received research support from GE Healthcare (paid to institution). F.B. acts as a consultant for Biogen-Idec, IXICO, Merck-Serono, Novartis, Combinostics, and Roche. He has received grants, or grants are pending, from the Amyloid Imaging to Prevent Alzheimer\u2019s Disease (AMYPAD) initiative, the Biomedical Research Centre at University College London Hospitals, the Dutch MS Society, ECTRIMS\u2013MAGNIMS, EU-H2020, the Dutch Research Council (NWO), the UK MS Society, and the National Institute for Health Research, University College London. He has received payments for the development of educational presentations from Ixico and his institution from Biogen-Idec and Merck. He is on the editorial board of Radiology, European Neuroradiology, Multiple Sclerosis Journal, and Neurology. Is on the board of directors of Queen Square Analytics. R.O. has received research support from Avid Radiopharmaceuticals, has given lectures in symposia sponsored by GE Healthcare and is an editorial board member of Alzheimer\u2019s Research & Therapy and the European Journal of Nuclear Medicine and Molecular Imaging. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy\/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. T.G.B. is a consultant for Aprinoia Therapeutics, Biogen and Avid Radiopharmaceuticals. A.A. has received, over the last 10 years, honoraria or support for consulting; participating in independent data safety monitoring boards; providing educational lectures, programs, and materials; or serving on advisory or oversight boards for AbbVie, Acadia, Allergan, the Alzheimer\u2019s Association, Alzheimer\u2019s Disease International, Axovant, AZ Therapies, Biogen, Eisai, Grifols, Harvard Medical School Graduate Continuing Education, JOMDD, Lundbeck, Merck, Prothena, Roche\/Genentech, Novo Nordisk, Qynapse, Sunovion, Suven, and Synexus. Dr. Atri receives book royalties from Oxford University Press for a medical book on dementia. Dr. Atri receives institutional research grant\/contract funding from NIA\/NIH 1P30AG072980, NIA\/NIH U22AG057437, AZ DHS CTR040636, Washington University St Louis, and Gates Ventures. Dr. Atri\u2019s institution receives\/received funding for clinical trial grants, contracts, and projects from government, consortia, foundations and companies for which he serves\/served as contracted site-PI. S.H.M. serves as a site co-investigator and receives funding for the PPMI study from the Michael J Fox Foundation. S.H.M. has received research funding from the Arizona Biomedical Research Consortium (ABRC) and International Essential Tremor Foundation (IETF). S.H.M. also has received funding for clinical trial grants, contracts, and projects from government and companies for which S.H.M. serves or has served as contracted site-PI. P.C. has received research support from Lewy Body Dementia association and Arizona Alzheimer\u2019s Consortium (both paid to institution). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5133"}}